Cromer Deborah, Schlub Timothy E, Smyth Redmond P, Grimm Andrew J, Chopra Abha, Mallal Simon, Davenport Miles P, Mak Johnson
Infection Analytics Program, Kirby Institute, UNSW Australia, Sydney NSW 2052, Australia.
Centre for Vascular Research, UNSW Australia, Sydney NSW 2052, Australia.
Viruses. 2016 Apr 22;8(4):118. doi: 10.3390/v8040118.
High rates of mutation and recombination help human immunodeficiency virus (HIV) to evade the immune system and develop resistance to antiretroviral therapy. Macrophages and T-cells are the natural target cells of HIV-1 infection. A consensus has not been reached as to whether HIV replication results in differential recombination between primary T-cells and macrophages. Here, we used HIV with silent mutation markers along with next generation sequencing to compare the mutation and the recombination rates of HIV directly in T lymphocytes and macrophages. We observed a more than four-fold higher recombination rate of HIV in macrophages compared to T-cells (p < 0.001) and demonstrated that this difference is not due to different reliance on C-X-C chemokine receptor type 4 (CXCR4) and C-C chemokine receptor type 5 (CCR5) co-receptors between T-cells and macrophages. We also found that the pattern of recombination across the HIV genome (hot and cold spots) remains constant between T-cells and macrophages despite a three-fold increase in the overall recombination rate. This indicates that the difference in rates is a general feature of HIV DNA synthesis during macrophage infection. In contrast to HIV recombination, we found that T-cells have a 30% higher mutation rate than macrophages (p < 0.001) and that the mutational profile is similar between these cell types. Unexpectedly, we found no association between mutation and recombination in macrophages, in contrast to T-cells. Our data highlights some of the fundamental difference of HIV recombination and mutation amongst these two major target cells of infection. Understanding these differences will provide invaluable insights toward HIV evolution and how the virus evades immune surveillance and anti-retroviral therapeutics.
高突变率和重组率有助于人类免疫缺陷病毒(HIV)逃避免疫系统并对抗逆转录病毒疗法产生耐药性。巨噬细胞和T细胞是HIV-1感染的天然靶细胞。关于HIV复制是否会导致原代T细胞和巨噬细胞之间的差异重组,尚未达成共识。在这里,我们使用带有沉默突变标记的HIV以及下一代测序技术,直接比较HIV在T淋巴细胞和巨噬细胞中的突变率和重组率。我们观察到,与T细胞相比,HIV在巨噬细胞中的重组率高出四倍多(p < 0.001),并证明这种差异并非由于T细胞和巨噬细胞对C-X-C趋化因子受体4型(CXCR4)和C-C趋化因子受体5型(CCR5)共受体的依赖程度不同所致。我们还发现,尽管总体重组率增加了三倍,但T细胞和巨噬细胞之间HIV基因组的重组模式(热点和冷点)保持不变。这表明,重组率的差异是巨噬细胞感染期间HIV DNA合成的一个普遍特征。与HIV重组不同,我们发现T细胞的突变率比巨噬细胞高30%(p < 0.001),并且这些细胞类型之间的突变谱相似。出乎意料的是,与T细胞不同,我们在巨噬细胞中未发现突变与重组之间的关联。我们的数据突出了HIV在这两种主要感染靶细胞中的重组和突变的一些根本差异。了解这些差异将为HIV进化以及病毒如何逃避免疫监视和抗逆转录病毒治疗提供宝贵的见解。